Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Antunes S, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Levesque Q, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Venditti A, Huls G, EORTC Leukemia Group, Italian Group for Adult Hematologic Diseases, and German MDS Study Group.

Open source

DOI
10.1016/j.bneo.2026.100246
Published
2026-05-13
Container
Blood Neoplasia
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.bneo.2026.100246,
  title = {Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.},
  author = {Lübbert M and  Wijermans PW and  Kicinski M and  Chantepie S and  Van der Velden WJFM and  Noppeney R and  Griškevičius L and  Neubauer A and  Crysandt M and  Vrhovac R and  Luppi M and  Fuhrmann S and  Audisio E and  Candoni A and  Legrand O and  Foà R and  Gaidano G and  van Lammeren-Venema D and  Posthuma EFM and  Hoogendoorn M and  Giraut A and  Antunes S and  Stevens-Kroef M and  Jansen JH and  de Graaf AO and  Efficace F and  Ammatuna E and  Levesque Q and  Wäsch R and  Becker H and  Blijlevens N and  Dührsen U and  Baron F and  Suciu S and  Venditti A and  Huls G and  EORTC Leukemia Group and  Italian Group for Adult Hematologic Diseases and  and German MDS Study Group.},
  year = {2026},
  journal = {Blood Neoplasia},
  doi = {10.1016/j.bneo.2026.100246},
  url = {https://doi.org/10.1016/j.bneo.2026.100246}
}

RIS

TY  - JOUR
TI  - Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.
AU  - Lübbert M
AU  -  Wijermans PW
AU  -  Kicinski M
AU  -  Chantepie S
AU  -  Van der Velden WJFM
AU  -  Noppeney R
AU  -  Griškevičius L
AU  -  Neubauer A
AU  -  Crysandt M
AU  -  Vrhovac R
AU  -  Luppi M
AU  -  Fuhrmann S
AU  -  Audisio E
AU  -  Candoni A
AU  -  Legrand O
AU  -  Foà R
AU  -  Gaidano G
AU  -  van Lammeren-Venema D
AU  -  Posthuma EFM
AU  -  Hoogendoorn M
AU  -  Giraut A
AU  -  Antunes S
AU  -  Stevens-Kroef M
AU  -  Jansen JH
AU  -  de Graaf AO
AU  -  Efficace F
AU  -  Ammatuna E
AU  -  Levesque Q
AU  -  Wäsch R
AU  -  Becker H
AU  -  Blijlevens N
AU  -  Dührsen U
AU  -  Baron F
AU  -  Suciu S
AU  -  Venditti A
AU  -  Huls G
AU  -  EORTC Leukemia Group
AU  -  Italian Group for Adult Hematologic Diseases
AU  -  and German MDS Study Group.
PY  - 2026
JO  - Blood Neoplasia
DO  - 10.1016/j.bneo.2026.100246
UR  - https://doi.org/10.1016/j.bneo.2026.100246
ER  -

APA

M, L., PW, W., M, K., S, C., WJFM, V. D. V., R, N., L, G., A, N., M, C., R, V., M, L., S, F., E, A., A, C., O, L., R, F., G, G., D, V. L., EFM, P., M, H., A, G., S, A., M, S., JH, J., AO, D. G., F, E., E, A., Q, L., R, W., H, B., N, B., U, D., F, B., S, S., A, V., G, H., Group, E. L., Diseases, I. G. F. A. H., & Group., A. G. M. S. (2026). Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.. Blood Neoplasia. https://doi.org/10.1016/j.bneo.2026.100246

Source records